SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
This rule would go beyond already controversial genetically modified organisms (GMOs) to encompass hundreds of new products of new gene and genome editing techniques. (Photo: Andrea Seaman/flickr/cc)
If the proposed rule becomes law, USDA will write a letter like this:
Dear Biotechnology Product Developer,
We write in response to your request that we affirm the validity of your self- determination that your GE product complies with USDA rules authorized by the Plant Protection Act. We grant your request. You may sell your product in the U.S. and in foreign countries, once you have received grants of self-determination validity from the Food and Drug Administration and the Environmental Protection Agency.
(FDA and EPA rules for self-determination will come all too soon.)
Unfortunately, this scenario is not science fiction, but the very likely result of USDA's proposed rule, if it is finalized. The deadline for public comment on the rule is August 5. IATP opposed the rule in a July 30 letter for several reasons, including:
USDA, in its desire to maximize trade in GE crops as soon as possible and everywhere, has proposed a rule that would make it exceedingly difficult to assess a GE plant's risks, even for the "unfamiliar products" that are targeted for USDA paperwork review, when GE product developers decide not to self-determine their compliance with the rule to increase acceptance of their products by foreign regulators in U.S. export targets . The classification of commercial applicant studies and data as "confidential business information" adds to a proposed rule that, as Professor Kuzma writes, "does not inspire public confidence."
Dear Common Dreams reader, The U.S. is on a fast track to authoritarianism like nothing I've ever seen. Meanwhile, corporate news outlets are utterly capitulating to Trump, twisting their coverage to avoid drawing his ire while lining up to stuff cash in his pockets. That's why I believe that Common Dreams is doing the best and most consequential reporting that we've ever done. Our small but mighty team is a progressive reporting powerhouse, covering the news every day that the corporate media never will. Our mission has always been simple: To inform. To inspire. And to ignite change for the common good. Now here's the key piece that I want all our readers to understand: None of this would be possible without your financial support. That's not just some fundraising cliche. It's the absolute and literal truth. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. Will you donate now to help power the nonprofit, independent reporting of Common Dreams? Thank you for being a vital member of our community. Together, we can keep independent journalism alive when it’s needed most. - Craig Brown, Co-founder |
If the proposed rule becomes law, USDA will write a letter like this:
Dear Biotechnology Product Developer,
We write in response to your request that we affirm the validity of your self- determination that your GE product complies with USDA rules authorized by the Plant Protection Act. We grant your request. You may sell your product in the U.S. and in foreign countries, once you have received grants of self-determination validity from the Food and Drug Administration and the Environmental Protection Agency.
(FDA and EPA rules for self-determination will come all too soon.)
Unfortunately, this scenario is not science fiction, but the very likely result of USDA's proposed rule, if it is finalized. The deadline for public comment on the rule is August 5. IATP opposed the rule in a July 30 letter for several reasons, including:
USDA, in its desire to maximize trade in GE crops as soon as possible and everywhere, has proposed a rule that would make it exceedingly difficult to assess a GE plant's risks, even for the "unfamiliar products" that are targeted for USDA paperwork review, when GE product developers decide not to self-determine their compliance with the rule to increase acceptance of their products by foreign regulators in U.S. export targets . The classification of commercial applicant studies and data as "confidential business information" adds to a proposed rule that, as Professor Kuzma writes, "does not inspire public confidence."
If the proposed rule becomes law, USDA will write a letter like this:
Dear Biotechnology Product Developer,
We write in response to your request that we affirm the validity of your self- determination that your GE product complies with USDA rules authorized by the Plant Protection Act. We grant your request. You may sell your product in the U.S. and in foreign countries, once you have received grants of self-determination validity from the Food and Drug Administration and the Environmental Protection Agency.
(FDA and EPA rules for self-determination will come all too soon.)
Unfortunately, this scenario is not science fiction, but the very likely result of USDA's proposed rule, if it is finalized. The deadline for public comment on the rule is August 5. IATP opposed the rule in a July 30 letter for several reasons, including:
USDA, in its desire to maximize trade in GE crops as soon as possible and everywhere, has proposed a rule that would make it exceedingly difficult to assess a GE plant's risks, even for the "unfamiliar products" that are targeted for USDA paperwork review, when GE product developers decide not to self-determine their compliance with the rule to increase acceptance of their products by foreign regulators in U.S. export targets . The classification of commercial applicant studies and data as "confidential business information" adds to a proposed rule that, as Professor Kuzma writes, "does not inspire public confidence."